Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106043 | 0.84 | KMO (0.46) | CASP7CASP6KMOKDM4ETP53 | |
| SCHEMBL5491933 | 0.81 | KMO (0.60) | KMOKDM4ETP53TSHRMEN1 | |
| SCHEMBL6079401 | 0.81 | KDM4E (0.44) | CASP7CASP6KMOKDM4ETP53 | |
| SCHEMBL3114681 | 0.79 | AKT1 (0.45) | KMOKMT2AALDH1A1POLBHTT | |
| SCHEMBL4167841 | 0.78 | CYP1A2 (0.52) | CASP7CASP6KMOKDM4ETP53 | |
| 3-Aminobenzamide SCHEMBL6079400 | 0.77 | LMNA (0.43) | CASP7CASP6KMOKDM4ETP53 | |
| SCHEMBL3232359 | 0.76 | HTT (0.52) | CASP7CASP6KDM4ETP53TSHR | |
| SCHEMBL5490793 | 0.76 | KMO (0.53) | KMOKDM4ETP53TSHRMEN1 | |
| SCHEMBL3100542 | 0.75 | KDM4E (0.49) | KMOKDM4ETP53TSHRMEN1 | |
| SCHEMBL3107301 | 0.73 | PIK3CA (0.46) | KMOKDM4EPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | CASP7 821/4885CASP6 897/4885KMO 4699/4885 |
| US-20060122156-A1 | Heteroaryl compounds | IL2, CCL11, IL4 | CASP7 484/4885CASP6 457/4885KMO 856/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | CASP7 229/4885CASP6 361/4885KMO 1654/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | CASP7 821/4885CASP6 897/4885KMO 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.